Tuesday, September 8

Browsing: Withdraws

Diagnosis

FDA Withdraws Adagrasib/Cetuximab Approval in KRAS G12C-Mutated CRC

By NewsCancerSeptember 8, 20260

The FDA has withdrawn the accelerated approval of adagrasib (Krazati) in combination with cetuximab (Erbitux) for adult patients with KRAS…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.